These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 28493045)

  • 1. Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer.
    Ruddy KJ; Van Houten HK; Sangaralingham LR; Freedman RA; Thompson CA; Hashmi SK; Jemal A; Haddad TC; Mougalian S; Herrin J; Gross C; Shah N
    Breast Cancer Res Treat; 2017 Aug; 164(3):515-525. PubMed ID: 28493045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.
    Leal AD; Van Houten H; Sangaralingham L; Freedman RA; Jemal A; Neuman HB; Haddad TC; Mutter RW; Keegan THM; Mougalian SS; Loprinzi CL; Gross CP; Shah N; Ruddy KJ
    Clin Breast Cancer; 2018 Aug; 18(4):e513-e520. PubMed ID: 29054689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
    Barcenas CH; Niu J; Zhang N; Zhang Y; Buchholz TA; Elting LS; Hortobagyi GN; Smith BD; Giordano SH
    J Clin Oncol; 2014 Jul; 32(19):2010-7. PubMed ID: 24868022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).
    Icli F; Akbulut H; Onur H; Yalcin B; Demirkazık A; Senler FÇ
    Breast; 2011 Apr; 20(2):155-7. PubMed ID: 20951586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
    Eiermann W; Pienkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press M; Sauter G; Lindsay MA; Riva A; Buyse M; Drevot P; Taupin H; Mackey JR
    J Clin Oncol; 2011 Oct; 29(29):3877-84. PubMed ID: 21911726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
    Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
    Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.
    Torres S; Trudeau M; Eisen A; Earle CC; Chan KKW
    Breast Cancer Res Treat; 2015 Jul; 152(1):137-145. PubMed ID: 26026467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.
    Enright K; Grunfeld E; Yun L; Moineddin R; Ghannam M; Dent S; Eisen A; Trudeau M; Kaizer L; Earle C; Krzyzanowska MK
    J Oncol Pract; 2015 Mar; 11(2):126-32. PubMed ID: 25604597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer.
    Roy C; Choudhury KB; Pal M; Saha A; Bag S; Banerjee C
    Indian J Cancer; 2012; 49(3):266-71. PubMed ID: 23238142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
    Spigel DR; Hainsworth JD; Burris HA; Molthrop DC; Peacock N; Kommor M; Vazquez ER; Greco FA; Yardley DA
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):280-6. PubMed ID: 21558987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer.
    Yardley DA; Burris HA; Farley CP; Barton JH; Peacock NW; Spigel DR; Greco FA; Hainsworth JD
    Clin Breast Cancer; 2008 Jun; 8(3):242-8. PubMed ID: 18650154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
    Jones SE; Savin MA; Holmes FA; O'Shaughnessy JA; Blum JL; Vukelja S; McIntyre KJ; Pippen JE; Bordelon JH; Kirby R; Sandbach J; Hyman WJ; Khandelwal P; Negron AG; Richards DA; Anthony SP; Mennel RG; Boehm KA; Meyer WG; Asmar L
    J Clin Oncol; 2006 Dec; 24(34):5381-7. PubMed ID: 17135639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study.
    R Ferreira A; Palha A; Correia L; Filipe P; Rodrigues V; Costa L; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; U Lin N; Vaz-Luís I
    Breast; 2016 Oct; 29():68-73. PubMed ID: 27468923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.
    Buyukhatipoglu H; Babacan T; Kertmen N; Balakan O; Suner A; Ates O; Sarici F; Aslan A; Diker O; Tasdemir V; Ozisik Y; Altundag K
    J BUON; 2015; 20(1):22-7. PubMed ID: 25778291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
    Chilcott J; Lloyd Jones M; Wilkinson A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
    Vriens BE; Aarts MJ; de Vries B; van Gastel SM; Wals J; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Borm GF; Tjan-Heijnen VC;
    Eur J Cancer; 2013 Oct; 49(15):3102-10. PubMed ID: 23850450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil).
    Hatam N; Ahmadloo N; Ahmad Kia Daliri A; Bastani P; Askarian M
    Arch Gynecol Obstet; 2011 Jul; 284(1):215-20. PubMed ID: 20740365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
    Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
    Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.